Volume
Open
Day's Low
Day's High
52 Wk Low
52 Wk High
Bid
Ask
EPS
PE Ratio
Shares
Market Cap
Dividend
Ex-Div Date
Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
...
Health Technology » Biotechnology
| symbol | company | %chng | last | %short | avg$volume | |
|---|---|---|---|---|---|---|
| AMGN | Amgen Inc. | -0.26% | 203.42 | 1.3% | $752.26m | |
| GILD | Gilead Sciences, Inc. | 0.14% | 64.22 | 0.9% | $374.75m | |
| CELG | Celgene Corporation | 0.03% | 95.71 | 1.3% | $325.97m | |
| ALXN | Alexion Pharmaceuticals, Inc. | 7.53% | 123.49 | 2.0% | $306.94m | |
| ILMN | Illumina, Inc. | -0.66% | 288.58 | 3.5% | $277.12m | |
| BIIB | Biogen Inc. | -0.48% | 232.06 | 1.3% | $268.05m | |
| VRTX | Vertex Pharmaceuticals Incorporated | -1.16% | 184.24 | 1.9% | $256.63m | |
| EXAS | Exact Sciences Corporation | -1.14% | 117.87 | 24.1% | $239.89m | |
| REGN | Regeneron Pharmaceuticals, Inc. | -0.93% | 295.02 | 2.6% | $203.40m | |
| A | Agilent Technologies, Inc. | -0.69% | 71.70 | 1.6% | $193.78m | |
| SRPT | Sarepta Therapeutics, Inc. | -6.34% | 95.07 | 14.7% | $184.59m | |
| BMRN | BioMarin Pharmaceutical Inc. | -1.05% | 77.40 | 4.3% | $97.47m | |
| INCY | Incyte Corporation | -0.59% | 85.56 | 2.5% | $96.06m | |
| GHDX | Genomic Health, Inc. | -1.12% | 73.52 | 1.8% | $85.99m | |
| SGEN | Seattle Genetics, Inc. | -2.01% | 78.36 | 6.5% | $79.57m |
Company Profile
Xenetic Biosciences, Inc. engages in the discovery, research, and development of next generation biologic drugs and novel orphan oncology therapeutics. Its lead investigational product candidate is oncology therapeutic XBIO-101 (sodium cridanimod), which focuses on the treatment of progesterone resistant endometrial cancer. It also offers proprietary drug development platform, PolyXen, which enables next-generation biologic drugs by improving their half-life and other pharmacological properties. The company was founded on August 9, 2011 and is headquartered in Framingham, MA.